Recombinant, human complement factor H (GEM103) granted Fast Track designation for dry age-related macular degeneration (AMD)

This investigational treatment is being evaluated in patients with complement factor H loss-of-function gene variants (approximately 40% of those with AMD). The ongoing Phase 2a ReGAtta study is evaluating GEM103 in patients with geographic atrophy secondary to dry AMD.

Source:

Biospace Inc.